These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
558 related articles for article (PubMed ID: 24602760)
21. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era. Nastoupil LJ; Sinha R; Byrtek M; Ziemiecki R; Zhou X; Taylor M; Friedberg JW; Link BK; Cerhan JR; Dawson K; Flowers CR Br J Haematol; 2016 Mar; 172(5):724-34. PubMed ID: 26729445 [TBL] [Abstract][Full Text] [Related]
22. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689 [TBL] [Abstract][Full Text] [Related]
23. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis. Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303 [TBL] [Abstract][Full Text] [Related]
24. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A; Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758 [TBL] [Abstract][Full Text] [Related]
25. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. Marcus R; Davies A; Ando K; Klapper W; Opat S; Owen C; Phillips E; Sangha R; Schlag R; Seymour JF; Townsend W; Trněný M; Wenger M; Fingerle-Rowson G; Rufibach K; Moore T; Herold M; Hiddemann W N Engl J Med; 2017 Oct; 377(14):1331-1344. PubMed ID: 28976863 [TBL] [Abstract][Full Text] [Related]
31. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
32. [Cost-effectiveness analysis of maintenance therapy with rituximab in patients with follicular lymphoma responding to induction therapy at the first line]. Castro Gómez AJ; López-Guillermo A; Rueda Domínguez A; Salar A; Varela Moreno C; Rubio-Terrés C Rev Esp Salud Publica; 2012; 86(2):163-76. PubMed ID: 22991059 [TBL] [Abstract][Full Text] [Related]
33. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. Vidal L; Gafter-Gvili A; Salles G; Dreyling MH; Ghielmini M; Hsu Schmitz SF; Pettengell R; Witzens-Harig M; Shpilberg O J Natl Cancer Inst; 2011 Dec; 103(23):1799-806. PubMed ID: 22021664 [TBL] [Abstract][Full Text] [Related]
34. Phase III study of watchful waiting vs. rituximab as first-line treatment in advanced stage follicular lymphoma with low tumour burden (JCOG1411, FLORA study). Miyamoto K; Fukuhara N; Maruyama D; Shibata T; Nakamura K; Ishizawa K; Tsukasaki K; Nagai H; Jpn J Clin Oncol; 2018 Aug; 48(8):777-780. PubMed ID: 29901705 [TBL] [Abstract][Full Text] [Related]
35. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744 [TBL] [Abstract][Full Text] [Related]
36. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. Solal-Céligny P; Bellei M; Marcheselli L; Pesce EA; Pileri S; McLaughlin P; Luminari S; Pro B; Montoto S; Ferreri AJ; Deconinck E; Milpied N; Gordon LI; Federico M J Clin Oncol; 2012 Nov; 30(31):3848-53. PubMed ID: 23008294 [TBL] [Abstract][Full Text] [Related]
37. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722 [TBL] [Abstract][Full Text] [Related]
38. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study. Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575 [TBL] [Abstract][Full Text] [Related]
39. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724 [TBL] [Abstract][Full Text] [Related]
40. Has single-agent rituximab replaced watch-and-wait for a patient with asymptomatic low-grade follicular lymphoma? Lowry L; Ardeshna KM Cancer J; 2012; 18(5):390-5. PubMed ID: 23006942 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]